BIA ALCL Cancer Risk Investigation
Textured Breast Implants
Have you developed ‘breast implant-associated anaplastic large cell lymphoma’ (BIA-ALCL) as a result of having textured breast implants?
We’re currently investigating this potential injustice and are encouraging women who believe they may have suffered as a result to contact us.
What is the current situation?
LHD Lawyers are currently investigating the potential for a class-action lawsuit regarding the use of banned, suspended and recalled breast implants by cosmetic surgeons, despite the implants being linked to the development of BIA-ALCL, among other health and safety risks.
As of January 2018, there were 359 reported cases of BIA-ALCL in women with breast implants, however health authorities suspect this is an underestimation. In May 2018, the TGA reported 72 cases of BIA-ALCL in Australia, which is disproportionally high in comparison to other countries. It has been suggested that this is because these dangerous models of breast implants were never banned in Australia.
It’s not clear why these breast implants carry a higher risk of BIA-ALCL, however, some theories suggest that it’s because the bacterial coatings (or biofilm) may trigger infections and inflammation.
Symptoms of BIA-ALCL include (but are not limited to):
- Breast pain
- Swelling or lumps
- Asymmetry of the breast
- Loss of appetite
- Night sweats
- Weight loss
- Enlarged lymph nodes
The Therapeutic Goods Administration (TGA) recently approved ‘special access’ to banned models of breast implants for six practitioners operating on 36 patients, despite having suspended the use of the implants for six months just four weeks earlier. They were suspended from use over their links to this rare form of cancer.
The recent recall and suspension of Cereform breast implants has resurrected the call for the establishment of an Australian national breast device registry. The development of a registry would enable the monitoring of breast implant devices and would allow for issues to be discovered as soon as possible. The Australian Federal Government has committed $3.6 million to the initiative, however, it currently remains at a standstill as a pilot project.
How can we help?
LHD Lawyers are currently accepting enquiries on behalf of women who have had breast implants inserted and believe they have suffered from BIA-ALCL as a result.
Breast implants are Class III (or ‘high risk’) medical devices. A new wave of lawsuits across the world is accusing breast implant manufacturers for failing to adequately test the implants for safety and failing to warn consumers about the side effects of use.
If you’re suffering from BIA-ALCL, we want to hear from you. Your enquiry with us is completely cost-free and will help us to achieve justice for women all over Australia who have suffered at the hands of irresponsible medical bodies and manufacturers.
We support you in demanding the TGA be more vigilant and patient-centred when it comes to testing the safety of breast implants before approving them, as the numbers of women suffering from complications continues to rise.
What will happen when I submit an enquiry?
You will receive an email confirming receipt of your enquiry with us. If you do not receive this email within 48 hours, please call LHD Lawyers on 02 9264 6644 or email firstname.lastname@example.org to confirm your registration.
How much will I have to pay?
LHD Lawyers are conducting research into this potential class action lawsuit on a ‘no win no fee’ basis. We believe that providing legal services in this manner provides true justice to those who have been affected. Submitting information to us won’t expose you to any out-of-pocket costs. Unless and until there is a successful outcome, all costs incurred will be covered by LHD Lawyers.
Enquire with us today so we can achieve justice for you and other women suffering from BIA-ALCL. You may be entitled to compensation for your hardship.
Request a free consultation
Please fill out your details below. One of our team will be in touch shortly to discuss your case.